The current study identified the synergistic anticancer effect of combined anti‐HER3 patritumab and anti‐HER2 pertuzumab for heregulin (HER3 ligand)‐expressing HER2‐positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.